What were the primary drivers of Boston Scientific's revenue growth in the reported periods?

Revenue growth was primarily driven by strong commercial execution and innovation across key business units, particularly within the Cardiovascular segment's Interventional Cardiology & Vascular Therapies and Electrophysiology units. The MedSurg segment also contributed positively, with growth in the Endoscopy business.

How did the company's profitability perform, and what contributed to the changes?

Profitability improved significantly. Net income attributable to common stockholders increased due to higher net sales and a favorable gross profit margin. A discrete tax benefit of $384 million recorded in the first half of 2026 also substantially boosted net income.

What are the implications of the announced restructuring plan for investors?

The approved 2026 Restructuring Plan, expected to incur $700-$800 million in pre-tax charges, aims to drive sustained cost efficiencies and support future growth. While it involves short-term costs, the projected annual pre-tax expense reduction of approximately $500 million suggests potential for improved operating leverage and profitability in the medium to long term. A substantial portion of the savings is expected to be reinvested in strategic growth initiatives.

What is the status of the pending Penumbra acquisition, and how will it be funded?

The acquisition of Penumbra, Inc., valued at approximately $14.5 billion, is progressing with regulatory reviews underway (FTC Second Request). Shareholder approval has been obtained. The transaction is expected to close in the second half of 2026 and will be funded by a combination of cash on hand and approximately $11.0 billion in new debt, with the remainder paid in Boston Scientific stock. This acquisition will be integrated into the Cardiovascular division.

BSX 10-Q Quarterly Report Q2 FY2026 — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-Q filed August 3, 2026. Cited figures are marked; the original filing is the authoritative source.

Boston Scientific Corporation (BSX) reported strong financial results for the three and six months ended June 30, 2026.

Net sales increased by 7.5% to $5.44 billion^a for the quarter and 9.5% to $10.65 billion for the six months, driven by robust performance in the Cardiovascular and MedSurg segments, particularly in Interventional Cardiology, Vascular Therapies, and Electrophysiology. Profitability also saw significant improvements. Net income attributable to common stockholders rose by 13.8% to $907 million for the quarter and a substantial 52.8% to $2.25 billion for the six months.

This growth was fueled by higher net sales and a notable discrete tax benefit recorded in the first half of the year. The company's operational and organic net sales growth underscore effective commercial execution and product innovation. Despite ongoing strategic investments in acquisitions and a new restructuring plan, the company maintained a healthy leverage ratio and ample liquidity.

02—Key points

Key Highlights

Net sales increased by 7.5% to $5.44 billion in Q2 2026 and 9.5% to $10.65 billion for the first six months of 2026, indicating strong top-line growth.
Net income attributable to common stockholders grew significantly by 13.8% to $907 million for Q2 2026 and 52.8% to $2.25 billion for the first six months of 2026.
Gross profit margin improved to 70.7% in Q2 2026 from 68.2% in Q2 2025, driven by higher-margin products and favorable pricing.
The company completed the acquisition of Nalu Medical, Inc. and has a pending acquisition of Penumbra, Inc., demonstrating a commitment to strategic growth through M&A.
Cash provided by operating activities remained strong at $1.82 billion for the first six months of 2026, indicating healthy cash generation.
The company executed a significant share repurchase program, buying back $2.00 billion of its common stock in Q2 2026, signaling confidence in its financial position and value.
A new global restructuring program (2026 Restructuring Plan) was approved, aiming for cost efficiencies with an estimated pre-tax charge of $700 million to $800 million.

03—Questions

Frequently Asked Questions

What were the primary drivers of Boston Scientific's revenue growth in the reported periods?
Revenue growth was primarily driven by strong commercial execution and innovation across key business units, particularly within the Cardiovascular segment's Interventional Cardiology & Vascular Therapies and Electrophysiology units. The MedSurg segment also contributed positively, with growth in the Endoscopy business.
How did the company's profitability perform, and what contributed to the changes?
Profitability improved significantly. Net income attributable to common stockholders increased due to higher net sales and a favorable gross profit margin. A discrete tax benefit of $384 million recorded in the first half of 2026 also substantially boosted net income.
What are the implications of the announced restructuring plan for investors?
The approved 2026 Restructuring Plan, expected to incur $700-$800 million in pre-tax charges, aims to drive sustained cost efficiencies and support future growth. While it involves short-term costs, the projected annual pre-tax expense reduction of approximately $500 million suggests potential for improved operating leverage and profitability in the medium to long term. A substantial portion of the savings is expected to be reinvested in strategic growth initiatives.
What is the status of the pending Penumbra acquisition, and how will it be funded?
The acquisition of Penumbra, Inc., valued at approximately $14.5 billion, is progressing with regulatory reviews underway (FTC Second Request). Shareholder approval has been obtained. The transaction is expected to close in the second half of 2026 and will be funded by a combination of cash on hand and approximately $11.0 billion in new debt, with the remainder paid in Boston Scientific stock. This acquisition will be integrated into the Cardiovascular division.

04—Continue

← View all 10-Q filings